ReviewPharmaceutics2021
Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Innovative Applications of Nanomaterials in the Diagnosis and Treatment of Ocular Diseases: Targeted Delivery, Intelligent Therapy, Diagnostic Breakthroughs, and Synergistic Strategies with Stem Cells and Biomaterials.International journal of nanomedicine · 2026Review
- Preparation andAdvanced pharmaceutical bulletin · 2025Article
- Nanomaterial-mediated antibiotic delivery: a novel strategy for osteomyelitis therapy.Frontiers in bioengineering and biotechnology · 2025Review
- Nanomedicine in Ophthalmology: From Bench to Bedside.Journal of clinical medicine · 2024Review
- Exploring Hydrogel Nanoparticle Systems for Enhanced Ocular Drug Delivery.Gels (Basel, Switzerland) · 2024Review
- Nanotechnological prospective for enhancing the antibacterial activity of mupirocin and cinnamon essential oil: a combination therapy.Frontiers in pharmacology · 2024Article
- Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment.Drug delivery · 2023Review
- The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems.Biomedicines · 2023Review
- Development of a Self-Assembled Hydrogels Based on Carboxymethyl Chitosan and Oxidized Hyaluronic Acid Containing Tanshinone Extract Nanocrystals for Enhanced Dissolution and Acne Treatment.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Review
- Shea Butter Potentiates the Anti-Bacterial Activity of Fusidic Acid Incorporated into Solid Lipid Nanoparticle.Polymers · 2022Article
- Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice.Pharmaceutics · 2022Article
- Lipid Nanoparticles for the Posterior Eye Segment.Pharmaceutics · 2021Review
- Nanocubosomal basedDrug delivery · 2021Article
- Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021Review
- Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective drug delivery to intraocular tissues remains a great challenge due to complex anatomical and physiological barriers that selectively limit the entry of drugs into the eye. To overcome these challenges, frequent topical application and regular intravitreal injections are currently used to achieve the desired drug concentrations into the eye. However, the repetitive installation or recurrent injections may result in several side effects. Recent advancements in the field of nanoparticle-based drug delivery have demonstrated promising results for topical ophthalmic nanotherapies in the treatment of intraocular diseases. Studies have revealed that nanocarriers enhance the intraocular half-life and bioavailability of several therapies including proteins, peptides and genetic material. Amongst the array of nanoparticles available nowadays, lipid-based nanosystems have shown an increased efficiency and feasibility in topical formulations, making them an important target for constant and thorough research in both preclinical and clinical practice. In this review, we will cover the promising lipid-based nanocarriers used in topical ophthalmic formulations for intraocular drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.